We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.64 | 0.98% | 1,092.75 | 1,092.59 | 1,093.38 | 1,100.08 | 1,079.0855 | 1,087.89 | 88,797 | 17:42:25 |
From Jul 2022 to Jul 2024
By Denny Jacob
Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9 patent claims were invalid.
Biotechnology company Regeneron said the Supreme Court's opinion ends a nearly decade-long patent dispute related to its PCSK9 inhibitor, Praluent.
"We're gratified that the Supreme Court has affirmed the position we have held for nearly ten years that Amgen's PCSK9 patents were overly broad and inconsistent with established case law," said Executive Vice President Joseph LaRosa.
According to an Amgen spokeswoman, the company is disappointed by the ruling, but "will continue to fight for patent laws and policies that provide meaningful patent protection needed to foster breakthrough innovation."
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 18, 2023 12:54 ET (16:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
